Retatrutide 50mg

Retatrutide 50mg Lyophilized Research Peptide: Advanced Technical & Structural Profile

Product Overview

The Retatrutide 50mg lyophilized powder represents a cutting-edge benchmark in multi-receptor agonist synthesis, engineered specifically for advanced laboratory investigations, receptor binding assays, and endocrine pathway modeling. As a unique single-molecule triple-agonist reference material, this compound simultaneously targets the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor. Distributed in high-capacity 50mg configurations, this pharmaceutical-grade lyophilized solid is designed to support high-throughput in-vitro protocols requiring superior purity standards (\ge 99\% verified via High-Performance Liquid Chromatography and Mass Spectrometry).

Structural Characteristics and Biochemical Properties

Molecular Formula: C256H392N64O79

Molecular Weight: 4,731.33 g/mol

Amino Acid Sequence: 39-residue modified peptide backbone featuring localized aminoisobutyric acid (Aib) substitutions, alpha-methyl-leucine, and a specialized C-terminal lysine conjugated with a hydrophilic linker and a C20 fatty diacid moiety.

CAS Number: 2381089-83-2

Appearance: White lyophilized solid cake, vacuum-sealed under an inert atmosphere to ensure maximum stability.

Solubility: Fully soluble in aqueous solutions and compatible with standard bacteriostatic diluents for analytical titration.

Mechanism of Action in Experimental Models

In controlled research settings, the primary utility of Retatrutide lies in its unique tripartite interaction profile across distinct G-protein coupled receptors:

1 GLP-1 Receptor Activation: Stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and modulates gastric transit rates to observe central satiety signaling pathways.

2 GIP Receptor Activation: Synergizes with GLP-1 pathways to optimize overall cellular energy partitioning, lipid metabolism, and receptor densitization dynamics.

3 Glucagon Receptor Agonism: Introduces a complementary energy-expenditure mechanism, stimulating hepatic lipolysis, fat oxidation pathways, and resting metabolic rate adjustments unique among multi-agonist peptides.

The inclusion of the C20 fatty diacid lipid chain facilitates strong reversible binding to serum albumin, extending the systemic half-life and supporting extended-duration in-vitro and in-vivo pharmacokinetic modeling.

Quality Assurance, Handling, and Storage Protocol

Purity Verification: Each individual batch undergoes rigorous third-party analytical testing, ensuring a verified purity threshold exceeding 99\% with complete documentation available via lot-specific Certificates of Analysis.

Lyophilized Storage: Store dry powder at -20^\circ\text{C} in a desiccated, dark environment protected from direct light and moisture exposure.

Reconstitution Guidelines: Reconstitute strictly using sterile bacteriostatic water, introducing the solvent gently down the inner glass wall to maintain structural integrity and avoid mechanical shearing of the peptide chain.

Post-Reconstitution Maintenance: Store reconstituted solutions between 2• C and 8• C, utilizing contents within standard experimental stability windows.

Regulatory Notice: This material is supplied strictly for laboratory research, analytical reference, and scientific evaluation purposes only. It is explicitly not approved for human consumption, clinical diagnostic application, or therapeutic administration.